Panitumumab - Amgen

Drug Profile

Panitumumab - Amgen

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; Clone-E7.6.3; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Novartis; Takeda; University of Texas M. D. Anderson Cancer Center; Wissenschaftlicher Service Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 31 Mar 2018 Takeda completes the phase I/II APOLLON trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in Japan (PO) (NCT02613221)
  • 08 Mar 2018 Takeda completes a phase I trial for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan (UMIN000015475)
  • 27 Feb 2018 University of Southern California and Amgen initiates enrolment in a phase III trial for Colorectal Cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT03300609)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top